Flagship Ventures hopes to create a new immune-microbiome company that will have a candidate in the clinic next year--through the combination of a pair of its…
French NASH and fibrosis disease biotech Inventiva is looking to build on its Big Pharma interest by filing for an IPO on the Euronext.
Early-stage Australian biotech AdAlta, which is targeting the lung-scarring disease idiopathic pulmonary fibrosis, is seeking to raise AU$10 million ($7.5…
Christine Placet has rounded up money for an ophthalmic gene therapy company, her first venture since leading Trophos to a $470 million takeover by Roche.
It’s an awkward age, to be 15. But that’s exactly where we are with the Fierce 15 this year.
Only 12 IPOs made it out last quarter from U.S. venture-backed companies. Of those, 9 were for biotech companies.
Aprecia Pharmaceuticals has secured $30 million in debt to launch the first 3-D printed pharmaceutical product and bring forward more 3-D printed fast-melt…
China upstart CStone Pharma has raised a major $150 million in a Series A funding drive as it looks to boost its research in immuno-oncology.
Cytune Pharma has secured €6 million to advance a modified version of interleukin-15 designed to stimulate natural killer and cytotoxic cells into the clinic.
A trio of strategic investors is buying into the next-gen oral integrin therapeutic startup Morphic in a big way with a new $51.5 million Series A financing.